ERBB2 and breast cancer: Mehta et al. [18] reported that patients with HER2-positive breast cancer who were assigned to a regimen of AC every 3 weeks or AC every 2 weeks followed by 13 weekly courses of paclitaxel (80 mg/m2), carboplatin (AUC of 2), and trastuzumab (4 mg/kg, followed by 2 mg/kg) showed pCR rates of 87.5 and 75%, respectively.